Prostate cancer: 5. Diagnostic tools for early detection

CMAJ. Canadian Medical Association Journal

Volumn 159, Issue 9, 1998, Pages 1139-1146

  Karakiewicz, Pierre I ^a   Aprikian, Armen G ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER DIAGNOSIS; CASE REPORT; EARLY DIAGNOSIS; HUMAN; MALE; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; URINALYSIS;

EID: 0031726342     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Catalona WJ. Screening for early detection of prostate cancer [letter]. Lancet 1996;347:1629.
2. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994;152:1905-9.
3. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994;152:1910-4.
4. Schroeder FH. Screening, early detection and treatment of prostate cancer: a European view. Urology 1995;46(3 suppl A):62-70.
5. Smith, DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate specific antigen. JAMA 1996;276:1309-15.
6. Aprikian AG, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, et al. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 1995;154:404-6.
7. Platt JF, Bree RL, Schwab RE. The accuracy of CT in the staging of carcinoma of the prostate. Am J Radiol 1977;1:281-9.
8. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 1990;323:621-6.
9. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995;45:70-4.
10. Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Aronson S, Nachabé M, et al. Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol 1996;155:605-6.
11. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996;156:873-7.
12. Bostwick DG. Prostate specific antigen: current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994;102(4 Suppl 1):S31-7.
13. Tchetgen MBN, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate specific antigen concentration. Urol Clin North Am 1997;24:283-91.
14. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996;155:3-9.
15. Terris MK, Stamey TA. Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. Br J Urol 1994;73:61-4.
16. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-68.
17. Karakiewicz PI, Bazinet M, Aprikian AG, Trudel C, Aronson S, Nachabé M, et al. Outcome of sextant biopsy according to gland volume. Urology 1997;49: 55-9.
18. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-9.
19. Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 1995;153:111-4.
20. Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, Nachabé M, et al. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44-51.
21. Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Aronson S, Nachabé M, et al. Reassessment of non-planimetric transrectal ultrasound prostate volume estimates. Urology 1996;47:857-62.
22. Karakiewicz PI, Bazinet M, Aprikian AG, Trudel C, Aronson S, Péloquin F, et al. Analysis of gland volume effect on the performance of PSA density in early detection of non-palpable, isoechoic prostate cancer. Can J Urol 1996;3: 212-20.
23. Karakiewicz PI, Aprikian AG, Meshref AW, Bazinet M. Computer-assisted comparative: analysis of four and six sector biopsies of the prostate. Urology 1996;48:747-50.
24. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159:471-6.
25. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age specific reference ranges. JAMA 1993;270: 860-4.
26. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate cancer. JAMA 1992;267:2215-7.
27. Catalona WJ, Smith DS, Ratliff TL. Value of measurement of the rate of change of serum PSA levels in prostate cancer screening [abstract 348]. J Urol 1993;149:300A.
28. Prestigiacomo AF, Stamey TA. Physiological variation of prostate specific antigen in the 4.0 to 10.0 ng/mL range in male volunteers. J Urol 1996;155:1977-80.
29. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997;157:2183-90.
30. Brawer MK, Beattie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 1993;150:106-11.
31. Carter HB, Morrel CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, et al. Estimation of prostatic growth using serial prostate specific antigen measurement in men with and without prostate cancer. Cancer Res 1992;52:3323-6.
32. Prestigiacomo AF, Stamey TA. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 1997;157:189-94.
33. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Patel A, Flanigan RC, et al. A multicenter trial evaluation of free PSA in the differentiation of prostate cancer from benign disease [abstract]. J Urol 1997;157:434A.
34. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurement. JAMA 1997; 277:1475-6.
35. Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results, and the potential applications of colour Doppler. Radiology 1993;186:509-13.
36. Alexander AA. To colour Doppler image the prostate or not: that is the question. Radiology 1995;195:11-3.
37. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
38. Karakiewicz PI, Bazinet M, Meshref AW, Aprikian AG, Trudel C, Aronson S, et al. Value of repeat ultrasonic prostatic biopsies following negative digitally directed biopsy. Can J Urol 1997;4:289-92.
39. Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Aronson S, Péloquin F, et al. Complications of ultrasound-guided prostate biopsy peripheral zone only versus peripheral and transition zone biopsy. Urol Oncol 1996;2:65-9.
40. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. Patient age and prostate gland size determine the appropriate number of cores per biopsy [abstract]. J Urol 1997;157:1428A.
41. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED Jr. The influence of prostate size on cancer detection. Urology 1990;46:831-6.
42. Karakiewicz PI, Hanley JA, Bazinet M. Prediction of cancer detection rates with sector biopsy ot the prostate: a three dimensional dynamic model [abstract]. J Urol 1996;155:259A.
43. Karakiewicz PI, Hanly JA, Bazinet M. Three-dimensional computer assisted analysis of sector biopsy of the prostate. Urology 1998;52:208-12.